36 citations
,
July 2022 in “Journal of Medicinal Chemistry” Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.
December 2016 in “University of Birmingham Institutional Research Archive (University of Birmingham)” Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
38 citations
,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
1 citations
,
September 2025 in “Dermatology and Therapy” GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
8 citations
,
September 2021 in “EMBO Molecular Medicine” A new small peptide may help hair growth by activating a specific receptor and should be tested in humans.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
October 2025 in “JEADV Clinical Practice” GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
1 citations
,
February 2014 in “Archiv Der Pharmazie” Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
December 2023 in “Journal of the Endocrine Society” Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
September 2025 in “Cureus” GLP-1 receptor agonists may cause hair loss, but more research is needed.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
September 2025 in “Wound Repair and Regeneration” GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
96 citations
,
October 1987 in “The Journal of Clinical Endocrinology & Metabolism” Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
135 citations
,
March 2000 in “Journal of Biological Chemistry” Agouti and AGRP affect pigmentation and obesity, with implications for metabolic disorders.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
May 1981 in “Inpharma (Balgowlah)” Medroxyprogesterone acetate improved sleep apnea symptoms in some obese patients.
17 citations
,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
5 citations
,
January 2005 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New steroids were effective in blocking male hormone receptors in hamster prostates.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.